Hepatitis B vaccine (recombinant, GlaxoSmithKline)

重组乙型肝炎疫苗(酿酒酵母)（葛兰素史克）

Report date: 2026/04/22 20:01:10

Base Information

Drug NameHepatitis B vaccine (recombinant, GlaxoSmithKline)
Drug Alias NameRecombinant Hepatitis B Vaccine(Saccharomyces cerevisiae) ( GlaxoSmithKline)Engerix-B安在时
ClassificationVaccines > Application > Prophylactic vaccineVaccines > National Immunization Program > Immunization program vaccine(Class I)
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHepatitis CPapillomavirus InfectionsHepatitis B, Chronic +[5] 
Global Approved IndicationsHepatitis B
Approved Indications in ChinaHepatitis B
Original Approved Country/TerritoryUnited States
Original Approved Date1989/08/28
Country/TerritoryCzechiaBelgiumUnited States +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesUniversity Of ValparaísoNational Institute On Drug AbuseNational Institute Of Allergy And Infectious Diseases (Niaid) +[4] 
Active IndicationsHepatitis B
Inactive IndicationsHepatitis CPapillomavirus InfectionsHepatitis B, Chronic +[4] 

Other Information

ATC CodeJ07BC01
Related LinksN/A